Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing genetically engineered allogeneic T cell product candidates for cancer and autoimmune diseases. The company's core business model revolves around creating "off-the-shelf" T cell therapies derived from healthy donors, designed to be readily available, scalable, and potentially more consistent than autologous therapies. Revenue generation is currently absent, as the company is in the development phase, incurring net losses since inception, with a reported net loss of $190.9 million ⁴ for the year ended December 31, 2025 ⁵ and an accumulated deficit of $2.0 billion ⁶ as of the same date. The company's strategy emphasizes repositioning allogeneic CAR T as a first-line consolidation approach in Large B-Cell Lymphoma (LBCL), expanding into autoimmune diseases, building state-of-the-art gene engineering and cell manufacturing capabilities, and leveraging next-generation technologies for solid tumors.

The company's product pipeline includes three core programs: cemacabtagene ansegedleucel (cema-cel, previously ALLO-501A) for Large B-Cell Lymphoma (LBCL), ALLO-316 for Renal Cell Carcinoma (RCC), and ALLO-329 for autoimmune diseases such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). Cema-cel targets CD19, a protein on B cells, and is being evaluated in the pivotal Phase 2 ALPHA3 trial for first-line (1L) LBCL consolidation. ALLO-316 targets CD70, highly expressed in RCC, and has completed enrollment in its Phase 1 TRAVERSE trial. ALLO-329, a dual-targeting CD19 and CD70 product, is in a Phase 1 clinical trial (RESOLUTION) for autoimmune diseases. The company has deprioritized other pipeline candidates to focus on these three core programs.

For the fiscal year ended December 31, 2025, Allogene Therapeutics, Inc. reported a net loss of $190.9 million ⁴. As of December 31, 2025, the company held $258.3 million ⁷ in cash and cash equivalents and investments. The company has incurred net losses in every period since its inception and anticipates incurring substantial net losses in the future, with an accumulated deficit of $2.0 billion ⁶ as of December 31, 2025 ⁵.

During 2025, Allogene initiated a Phase 1 clinical trial (RESOLUTION) of ALLO-329 for autoimmune diseases. A significant operational development was the discontinuation of dosing in the fludarabine, cyclophosphamide, and ALLO-647 (FCA) arm of the ALPHA3 trial in August 2025 ⁸, following a Grade 5 treatment-related serious adverse event. Consequently, further development of ALLO-647 was terminated, and the ALPHA3 trial is now proceeding with only the fludarabine and cyclophosphamide (FC) arm and the observation arm. In December 2025 ⁹, Foresight Diagnostics, a partner providing the CLARITY™ MRD test for the ALPHA3 trial, was acquired by Natera, Inc. In October 2024 ¹⁰, ALLO-316 received Regenerative Medicine Advanced Therapy (RMAT) designation for adult patients with advanced or metastatic RCC.

Management anticipates announcing MRD clearance data from the interim futility analysis of the ALPHA3 trial in April 2026 ¹¹. Enrollment in the ALPHA3 trial is expected to be completed by the end of 2027 ¹². Initial proof-of-concept data for ALLO-329 from the first patients treated in the RESOLUTION trial's first dosing cohorts are expected in June 2026 ¹³.

The company's primary growth area is the repositioning of its allogeneic CAR T product, cema-cel, as part of a first-line (1L) consolidation approach for newly diagnosed and treated LBCL patients who are likely to relapse. The ALPHA3 trial, initiated in June 2024 ¹⁴, leverages an investigational diagnostic test from Foresight Diagnostics to identify minimal residual disease (MRD) positive patients after 1L chemoimmunotherapy. The trial aims to evaluate if cema-cel improves clinical outcomes in these patients, with event-free survival (EFS) as its primary endpoint. The company believes that administering CAR T therapies to patients with low disease burden improves safety and efficacy, positioning cema-cel as a potential "7th cycle" of frontline treatment.

Another major growth vector is the expansion of the allogeneic CAR T platform into autoimmune diseases (AID) with ALLO-329. This next-generation product candidate targets both CD19 and CD70 and incorporates the Dagger® technology, designed to reduce or eliminate the need for standard chemotherapy by preventing premature rejection. The Phase 1 RESOLUTION trial, initiated in 2025 ¹⁵, is a rheumatology basket study evaluating ALLO-329 in SLE, IIM, and SSc, with two parallel dose escalation arms, one using cyclophosphamide alone and another with no lymphodepletion. The company plans to announce initial proof-of-concept data in June 2026 ¹³, which will include early clinical outcomes and translational data such as disease-related biomarkers, CAR T expansion, and immune reconstitution. ALLO-329 received three Fast Track Designations (FTD) from the FDA for SLE, IIM, and SSc on April 27, 2025 ¹⁶.

The company plans to continue investing in process science, product characterization, and manufacturing to improve its manufacturing processes, production, and supply chain capabilities. Cell Forge 1 (CF1), the company's manufacturing facility in Newark, California, is exclusively utilized for manufacturing product candidates for clinical studies. The company aims to maintain a robust supply chain with redundant sources, including internal and external infrastructure. In May 2025 ¹⁷, the company implemented a targeted reduction in manufacturing activities and related headcount to focus resources on critical clinical programs, believing it holds sufficient inventory of cema-cel, ALLO-329, and ALLO-316 for near-term clinical needs.

The company anticipates incurring significant expenditures for the foreseeable future, with these expenditures expected to increase as research and development continues and regulatory approvals are sought for product candidates. Substantial additional financing will be required for commercial production and registrational trials for multiple products in multiple regions, as well as for launching and commercializing product candidates if approved. As of December 31, 2025 ⁵, the company had $258.3 million ⁷ in cash and cash equivalents and investments.

The company faces significant risks, including the inherent uncertainty and substantial upfront capital expenditures associated with biopharmaceutical product development, leading to anticipated substantial net losses and the need for significant additional financing to complete development and commercialization ¹⁸. Adverse developments in financial markets, such as bank failures, could impair access to uninsured funds, impacting business operations and financial condition ¹⁹. The novel technologies underlying product candidates, such as gene-editing and the Dagger® platform, present challenges in predicting development time and cost, and the likelihood of regulatory approval, with risks of unforeseen expenses, delays, and manufacturing issues ²⁰. The discontinuation of the FCA arm in the ALPHA3 trial due to a Grade 5 serious adverse event highlights safety risks, which could lead to further regulatory actions, negative perceptions, and product liability claims ²¹. The unproven nature of CAR T therapy as a first-line consolidation strategy for LBCL patients introduces significant regulatory, commercial, and operational risks, including potential reluctance from physicians and patients, and challenges in obtaining adequate reimbursement ²². Delays in regulatory approval for the CLARITY™ assay outside the U.S., especially following Foresight Diagnostics' acquisition by Natera, could protract clinical development timelines and impact commercialization ²³. The company is heavily reliant on partners like Cellectis and Servier for gene editing technology, and Foresight Diagnostics for the CLARITY™ MRD test, with potential for loss of rights or disruptions if these partners fail to meet obligations or if litigation, such as the Factor Litigation, impacts access to critical technologies ²⁴. Reduced manufacturing operations following a May 2025 ¹⁷ workforce reduction may limit timely support for development programs, potentially delaying regulatory submissions and commercialization efforts ²⁵. The company also faces intense competition from other biotechnology and pharmaceutical companies, including those developing autologous, allogeneic, and in vivo cell therapies, as well as other therapeutic modalities, which could limit demand and pricing for its products ²⁶.

Management emphasizes a commitment to accelerating the development of allogeneic CAR T cell therapies, with the driving purpose of delivering readily available treatments faster, more reliably, at greater scale, and to more patients. The company anticipates multiple clinical readouts in the second quarter of 2026 ²⁷ that could validate key scientific and clinical assumptions underlying off-the-shelf CAR T therapy, including biologic activity, safety, and feasibility across oncology and autoimmune indications. The three strategic priorities are: repositioning cema-cel as a first-line consolidation approach in LBCL, expanding the allogeneic CAR T platform into autoimmune diseases with ALLO-329, and building state-of-the-art gene engineering and cell manufacturing capabilities. Management expects to announce MRD clearance data from the interim futility analysis of the ALPHA3 trial in April 2026 ¹¹ and initial proof-of-concept data for ALLO-329 in June 2026 ¹³. Enrollment in ALPHA3 is anticipated to be completed by the end of 2027 ¹².